Medicure Inc (MCUJF) 1.9000 $MCUJF
Medicure Comments on Recent Trading Activity
Marketwire - Tue Apr 15, 1:04PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, reports that, in view of the recent market activity in the Company's stock, the Investment Industry Regulatory Organization of Canada ("IIROC" has contacted the Company in accordance with its usual practice.
Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services
Marketwire - Mon Apr 14, 7:03AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced it has entered into an arrangement with Knight Therapeutics Inc. (TSX VENTURE: GUD), under which Knight will provide advisory services to help advance Medicure's U.S. specialty pharmaceutical business and corporate development initiatives.
Medicure Reports Financial Results for the Third Quarter Fiscal 2014
Marketwire Canada - Wed Mar 26, 4:11PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE:MPH) (OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014.
Medicure Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 4:00AM CDT
Summary
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013.
Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicure Announces Grant of Options
Marketwire - Fri May 10, 2:43PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(PINKSHEETS: MCUJD) announces today that the Board of Directors has approved the grant of an aggregate of 463,000 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. These options entitle the holders thereof to acquire, on or before the tenth anniversary of the date of grant, up to 463,000 common shares of the Company at an exercise price of $0.30 per share. The options are subject to the approval of the TSX Venture Exchange. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option.
Medicure Reports Third Quarter Financial Results for Fiscal 2013
Marketwire - Mon Apr 29, 3:31PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2013.
Dr. Albert D. Friesen to File Early Warning Report
Marketwire - Thu Feb 28, 6:31AM CST
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reports that since July 18, 2011 Dr. Albert D. Friesen has acquired shares exceeding 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on February 27, 2013 with the acquisition of 6,000 common shares of Medicure representing approximately 0.05% of the Company's outstanding common shares (the "Acquisition" . The shares were purchased at a price of $0.34 per share through the facilities of the TSX Venture Exchange for investment purposes. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion.
Medicure Comments on Recent Trading Activity
Marketwire - Tue Apr 15, 1:04PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, reports that, in view of the recent market activity in the Company's stock, the Investment Industry Regulatory Organization of Canada ("IIROC" has contacted the Company in accordance with its usual practice. Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services
Marketwire - Mon Apr 14, 7:03AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced it has entered into an arrangement with Knight Therapeutics Inc. (TSX VENTURE: GUD), under which Knight will provide advisory services to help advance Medicure's U.S. specialty pharmaceutical business and corporate development initiatives. Medicure Reports Financial Results for the Third Quarter Fiscal 2014
Marketwire Canada - Wed Mar 26, 4:11PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE:MPH) (OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014. Medicure Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 4:00AM CDT
Summary
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013. Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicure Announces Grant of Options
Marketwire - Fri May 10, 2:43PM CDT
Medicure Inc. (the "Company"
(TSX VENTURE: MPH)(PINKSHEETS: MCUJD) announces today that the Board of Directors has approved the grant of an aggregate of 463,000 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. These options entitle the holders thereof to acquire, on or before the tenth anniversary of the date of grant, up to 463,000 common shares of the Company at an exercise price of $0.30 per share. The options are subject to the approval of the TSX Venture Exchange. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option. Medicure Reports Third Quarter Financial Results for Fiscal 2013
Marketwire - Mon Apr 29, 3:31PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2013. Dr. Albert D. Friesen to File Early Warning Report
Marketwire - Thu Feb 28, 6:31AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(PINKSHEETS: MCUJF), a specialty pharmaceutical company, today reports that since July 18, 2011 Dr. Albert D. Friesen has acquired shares exceeding 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on February 27, 2013 with the acquisition of 6,000 common shares of Medicure representing approximately 0.05% of the Company's outstanding common shares (the "Acquisition" . The shares were purchased at a price of $0.34 per share through the facilities of the TSX Venture Exchange for investment purposes. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion. 
